ATE439346T1 - Verbindungen mit wachstumshormon freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon freisetzenden eigenschaften

Info

Publication number
ATE439346T1
ATE439346T1 AT99919125T AT99919125T ATE439346T1 AT E439346 T1 ATE439346 T1 AT E439346T1 AT 99919125 T AT99919125 T AT 99919125T AT 99919125 T AT99919125 T AT 99919125T AT E439346 T1 ATE439346 T1 AT E439346T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
disubstituted
Prior art date
Application number
AT99919125T
Other languages
English (en)
Inventor
Thomas Hansen
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE439346T1 publication Critical patent/ATE439346T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT99919125T 1998-05-11 1999-05-10 Verbindungen mit wachstumshormon freisetzenden eigenschaften ATE439346T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK63698 1998-05-11
DKPA199800875 1998-07-01
PCT/DK1999/000260 WO1999058501A1 (en) 1998-05-11 1999-05-10 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE439346T1 true ATE439346T1 (de) 2009-08-15

Family

ID=26064372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919125T ATE439346T1 (de) 1998-05-11 1999-05-10 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Country Status (23)

Country Link
EP (1) EP1077941B1 (de)
JP (2) JP4142253B2 (de)
KR (1) KR100593601B1 (de)
CN (1) CN1142911C (de)
AT (1) ATE439346T1 (de)
AU (1) AU757217B2 (de)
BR (1) BR9910329A (de)
CA (1) CA2329881C (de)
CY (1) CY1109626T1 (de)
CZ (1) CZ301276B6 (de)
DE (1) DE69941255D1 (de)
DK (1) DK1077941T3 (de)
ES (1) ES2331102T3 (de)
HU (1) HUP0102071A3 (de)
IL (2) IL139090A0 (de)
NO (1) NO318080B1 (de)
PL (1) PL194560B1 (de)
PT (1) PT1077941E (de)
RU (1) RU2243215C2 (de)
SI (1) SI1077941T1 (de)
TW (1) TWI222969B (de)
UA (1) UA72210C2 (de)
WO (1) WO1999058501A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60021521T4 (de) 1999-09-29 2006-09-21 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamide zur behandlung von integrin vermittelten störungen
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
AU2002230665A1 (en) 2000-12-06 2002-06-18 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
DE10113604A1 (de) * 2001-03-20 2002-10-24 Ibfb Gmbh Privates Inst Fuer B Verfahren zur Spaltung des humanen Wachstumshormons GH
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
EP1407779A1 (de) 2002-10-10 2004-04-14 Gastrotech A/S Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1735055A1 (de) * 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Verfahren zur verringerung von c-reaktivem protein mit wachstumshormon-sekretagoga
EP2298760B1 (de) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Kristallformen von (3R)-1-(2-Methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidin-carbonsäure-1,2,2-trimethylhydrazid
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CA2656398A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2012131090A1 (en) 2011-03-31 2012-10-04 Galderma Research & Development Method for treatment of xeroderma pigmentosum
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1174504A (zh) * 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (de) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
WO1998010653A1 (en) * 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP2001502319A (ja) * 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体

Also Published As

Publication number Publication date
KR100593601B1 (ko) 2006-06-28
CN1300281A (zh) 2001-06-20
PL194560B1 (pl) 2007-06-29
NO20005668D0 (no) 2000-11-10
AU757217B2 (en) 2003-02-06
ES2331102T3 (es) 2009-12-21
EP1077941B1 (de) 2009-08-12
CY1109626T1 (el) 2014-08-13
RU2243215C2 (ru) 2004-12-27
UA72210C2 (uk) 2005-02-15
DK1077941T3 (da) 2009-12-07
TWI222969B (en) 2004-11-01
SI1077941T1 (sl) 2010-01-29
BR9910329A (pt) 2001-01-30
JP2004500312A (ja) 2004-01-08
CN1142911C (zh) 2004-03-24
JP2008156372A (ja) 2008-07-10
CA2329881C (en) 2010-03-16
JP4142253B2 (ja) 2008-09-03
AU3701099A (en) 1999-11-29
KR20010043422A (ko) 2001-05-25
IL139090A0 (en) 2001-11-25
HUP0102071A3 (en) 2002-06-28
JP4938708B2 (ja) 2012-05-23
PL344042A1 (en) 2001-09-24
CZ20004129A3 (en) 2001-06-13
NO318080B1 (no) 2005-01-31
WO1999058501A1 (en) 1999-11-18
DE69941255D1 (de) 2009-09-24
IL139090A (en) 2007-03-08
NO20005668L (no) 2001-01-10
EP1077941A1 (de) 2001-02-28
PT1077941E (pt) 2010-07-01
CA2329881A1 (en) 1999-11-18
CZ301276B6 (cs) 2009-12-30
HUP0102071A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
DE69941255D1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
BG105256A (en) Muscarinic agonists and antagonists
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
BG103558A (en) Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
BG104916A (en) Calcilytic compounds
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
DE59900546D1 (de) Pseudoböhmit und gamma al2o3 enthaltender trägerkatalysator, dessen herstellung und dessen verwendung zur herstellung von 1,2-dichlorethan
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
ATE500269T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE60003943D1 (de) Trimegestone enthaltende pharmazeutische zusammensetzungen
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
DE69426021D1 (de) Xamonelin-Tartrat
DE69921611D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69919195D1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
DE68900131D1 (de) Biozide 4,5-dichlor-1,2-dithiol-3-on-zusammensetzung.
MY102063A (en) New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
UA67058A (en) Composition for treating periodontitis
PE61999A1 (es) Compuestos de tetrahidropiridina
IT8919173A0 (it) Dispositivo per la decomposizione di rifiuti vegetali ed animali, nonche' suo impiego.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1077941

Country of ref document: EP